IN10018

Phase 2Small molecule

IInxMed (Shanghai) Co., Ltd.

IN10018 is one of 167 small molecule programs targeting Cervical Adenocarcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

166

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cervical AdenocarcinomaRecruiting

Pancreatic CancerRecruiting

Ovarian CancerRecruiting

Solid TumorActive, not recruiting

KRAS G12C MutationRecruiting

Combination TherapyNot yet recruiting

Cervical AdenocarcinomaPhase 2

Recruiting

Pancreatic CancerPhase 2

Recruiting

Ovarian CancerPhase 2

Recruiting

Solid TumorPreclinical

Active, not recruiting

KRAS G12C MutationPhase 1

Recruiting

Combination TherapyPhase 2

Not yet recruiting

Competition

Competitive Landscape

348 competitors in Solid Tumor

#DrugCompanyPhaseTrials

IN10018

IInxMed (Shanghai) Co., Ltd.

Phase 2

1 2

Fludara

Sanofi

Preclinical

2 3

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

3 4

Paxil

SSebela Pharmaceuticals Development LLC

Preclinical

1 5

Proleukin

IIovance Biotherapeutics, Inc.

Preclinical

1 6

PD-1 Inhibitor

Johnson & Johnson

Preclinical

2 7

Soc

Pfizer

Preclinical

1 8

Tulmimetostat

Novartis

Preclinical

1 9

Interleukin 2

EEssen Biotech

Preclinical

2 10

IL-2

FFate Therapeutics

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Ovarian Cancer

NCT06014528

Phase 1/2Not yet recruiting

Combination Therapy

NCT05982522

Q4 2027

Phase 1Recruiting

KRAS G12C Mutation

NCT06946927

Q3 2029

PreclinicalActive, not recruiting

Solid Tumor

NCT05379946

Q3 2030

Phase 3Recruiting

Non-Small Cell Lung Cancer

NCT07174908

Clinical

Trials by Indication[1]

Combination Therapy3 trials

IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC

Recruiting·IInxMed (Shanghai) Co., Ltd.·Phase 1/2·NCT05994131·110 enrolled

IN10018 Combination Therapy in Previously-treated Solid Tumors

Not yet recruiting·IInxMed (Shanghai) Co., Ltd.·Phase 1/2·NCT05982522·72 enrolled

IN10018 Combination Therapy in Treatment-naïve ES-SCLC

Recruiting·IInxMed (Shanghai) Co., Ltd.·Phase 1/2·NCT06030258·120 enrolled

Ovarian Cancer2 trials

IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer

Recruiting·IInxMed (Shanghai) Co., Ltd.·Phase 2·NCT06014528·168 enrolled

IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer

Recruiting·IInxMed (Shanghai) Co., Ltd.·Phase 1/2·NCT05551507·150 enrolled

Cervical Adenocarcinoma1 trial

IN10018 With Nab-Paclitaxel and Cadonilimab for Metastatic or Recurrent Gastric-Type Cervical Adenocarcinoma: Phase 2 Trial

Recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 2·NCT06654011·25 enrolled

Non-Small Cell Lung Cancer1 trial

A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation

Recruiting·IInxMed (Shanghai) Co., Ltd.·Phase 3·NCT07174908·400 enrolled

Locally Advanced or Metastatic Solid Tumors1 trial

IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors

Recruiting·IInxMed (Shanghai) Co., Ltd.·Phase 1/2·NCT07441174·92 enrolled

5 more indications

Pancreatic Cancer1 trial

IN10018+ Standard Chemotherapy (+KN046) in Subjects With Advanced Pancreatic Cancer

Recruiting·IInxMed (Shanghai) Co., Ltd.·Phase 1/2·NCT05827796·70 enrolled

Adenocarcinoma1 trial

IN10018 Monotherapy or in Combination With Docetaxel in Gastric or GEJ Adenocarcinoma

Completed·IInxMed (Shanghai) Co., Ltd.·Phase 1·NCT05327231·33 enrolled

Metastatic Melanoma1 trial

IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma

Completed·IInxMed (Shanghai) Co., Ltd.·Phase 1·NCT04109456·51 enrolled

KRAS G12C Mutation1 trial

A Phase Ib Study of JMKX001899 in Combination With Other Therapies in Advanced NSCLC Harboring KRAS G12C Mutation

Recruiting·JJemincare·Phase 1·NCT06946927·72 enrolled

Solid Tumor1 trial

A Phase 1/2, Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of D-1553 in Combination With IN10018 in Subjects With Advanced or Metastatic Solid Tumors With KRasG12C Mutation

Active, not recruiting·IInventisBio Co., Ltd·Preclinical·NCT05379946·92 enrolled

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for IN10018. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IN10018 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IN10018. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — InxMed (Shanghai) Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: IInxMed (Shanghai) Co., Ltd.

IN10018

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2027

Q3 2029

Q3 2030

Trials by Indication[1]

Combination Therapy3 trials

Ovarian Cancer2 trials

Cervical Adenocarcinoma1 trial

Non-Small Cell Lung Cancer1 trial

Locally Advanced or Metastatic Solid Tumors1 trial

Pancreatic Cancer1 trial

Adenocarcinoma1 trial

Metastatic Melanoma1 trial

KRAS G12C Mutation1 trial

Solid Tumor1 trial

References

Drug Info

Quick Facts

Related News